-
公开(公告)号:CZ172997A3
公开(公告)日:1997-12-17
申请号:CZ172997
申请日:1997-06-04
Applicant: HOECHST AG
Inventor: STILZ HANS ULRICH DR , BECK GERHARD DR , RADAU MANFRED DR
IPC: C07D233/78 , A61K31/415 , A61K31/416 , A61K31/4164 , A61K31/4166 , A61P7/02 , A61P9/00 , A61P9/10 , A61P9/14 , A61P35/00 , A61P35/04 , C07D233/72 , C07D233/74 , C07D233/76 , A61K31/395
Abstract: Ethyl 3-(2-(4-(4-(aminoiminomethyl)phenyl)-4-methyl-2,5-dioxoimidazolidin-1- yl)acetylamino)-3-phenylpropionate hydrogen maleate of formula (I) is new. HB = maleic acid. All stereoisomers and their mixtures and salts are included.
-
公开(公告)号:DE19622489A1
公开(公告)日:1997-12-11
申请号:DE19622489
申请日:1996-06-05
Applicant: HOECHST AG
Inventor: STILZ HANS ULRICH DR , BECK GERHARD DR , RADAU MANFRED DR
IPC: C07D233/78 , A61K31/415 , A61K31/416 , A61K31/4164 , A61K31/4166 , A61P7/02 , A61P9/00 , A61P9/10 , A61P9/14 , A61P35/00 , A61P35/04 , C07D233/72 , C07D233/74 , C07D233/76 , C07C57/145
Abstract: Ethyl 3-(2-(4-(4-(aminoiminomethyl)phenyl)-4-methyl-2,5-dioxoimidazolidin-1- yl)acetylamino)-3-phenylpropionate hydrogen maleate of formula (I) is new. HB = maleic acid. All stereoisomers and their mixtures and salts are included.
-
公开(公告)号:CZ293351B6
公开(公告)日:2004-04-14
申请号:CZ359997
申请日:1997-11-13
Applicant: HOECHST AG
Inventor: STILZ HANS ULRICH DR , WEHNER VOLKMAR DR , KNOLLE JOCHEN DR , BARTNIK ECKART DR , HULS CHRISTOPH DR
IPC: C07D233/00 , A61K31/415 , A61K31/4166 , A61K31/4178 , A61K31/421 , A61K31/426 , A61K38/00 , A61K38/06 , A61K38/07 , A61K38/39 , A61P3/08 , A61P9/00 , A61P9/10 , A61P11/00 , A61P19/02 , A61P29/00 , A61P33/02 , A61P35/00 , A61P37/00 , A61P37/08 , A61P43/00 , C07D233/32 , C07D233/72 , C07D233/74 , C07D233/76 , C07D233/86 , C07D257/00 , C07D403/12 , C07D405/12 , C07K5/02 , C07K5/023 , C07K5/078 , C07K5/08 , C07K5/097 , C07K5/10 , C07K5/117 , C07K7/06 , C07K14/78
Abstract: In the present invention, there are disclosed compounds of the general formula I, in which the symbols B, D, E, R, W, Y, Z, b, c, d, e, f, g and h have specific meanings. These compounds are inhibitors of adhesion and migration of leukocytes and/or antagonists of VLA-4 adhesion receptor, which pertains to the group of integrins. Described is also the use of the compounds of the general formula I for preparing medicaments intended for treating or prophylaxis of diseases caused by undesired extent of leukocyte adhesion and/or migration or in which the cell-cell or cell-matrix interaction play a role, which are based on interaction of VLA-4 receptors with ligands thereof, such as inflammatory processes, rheumatic arthritis or allergic diseases. Further described are novel compounds of the general formula I per se as well as pharmaceutical compositions in which the novel compounds are comprised.
-
公开(公告)号:ES2202533T3
公开(公告)日:2004-04-01
申请号:ES97119639
申请日:1997-11-10
Applicant: HOECHST AG
Inventor: STILZ HANS ULRICH DR , WEHNER VOLKMAR DR , HULS CHRISTOPH DR , SEIFFGE DIRK DR
IPC: A61K31/415 , A61K31/4166 , A61K38/00 , A61K38/05 , C07D233/76 , A61K38/06 , A61K38/07 , A61P3/08 , A61P9/00 , A61P9/10 , A61P11/00 , A61P19/02 , A61P29/00 , A61P33/02 , A61P35/00 , A61P37/00 , A61P37/08 , A61P43/00 , C07D233/54 , C07D233/72 , C07K5/02 , C07K5/023 , C07K5/06 , C07K5/08 , C07K5/10 , C07K5/117
Abstract: Use of N-substituted pyrrolidone, imidazolidinone, oxazolidinone or thiazolidinone derivatives of formula (I), in all stereoisomer or mixture forms, or their salts is for inhibiting the adhesion and/or migration of leukocytes or inhibiting VLA-4 receptors is new. W = R1-A-CR13 or R1A-CH=C; Y = CO, CS or CH2; Z = O, S or CH2 etc.; A = 1-6C alkylene, 3-12C cycloalkylene, (1-6C), phenylene-(1-6C)alkyl, or the divalent residue of a 5- or 6-membered ring containing 1 or 2 N (optionally mono- or disubstituted) etc.; B = 1-6C alkylene (optionally substituted), 2-6C alkenylene, phenylene, phenylene-(1-3C) alkyl or (1-3C) alkylene-phenyl; D = CR2R3. NR3 or CH=CR3; E = tetrazolyl, SO3H etc.; R = H, alkyl, cycloalkyl, cycloalkylalkyl, Ar, Ar-alkyl, Het' or Het'-alkyl (where alkyl residues are optionally substituted); R1 = H, 1-10C alkyl (optionally fluorinated), cycloalkyl, cycloalkylalkyl, O or S etc.; R2 = H, alkyl, Ar, Ar-alkyl or 3-8C cycloalkyl; R3 = H, alkyl, Ar, Ar-alkyl, 3-8C cycloalkyl, alkenyl, alkynyl, alkenylcarbonyl, alkynylcarbonyl, pyridyl etc.; R13 = H, 1-6C alkyl, Ar-alkyl or 3-8C cycloalkyl; b, c, d, f = 0 or 1, but not all 0; e, g, h= 0-6; Ar = optionally substituted 6-14C aryl; Het' = optionally substituted heteroaryl; unless specified otherwise alkyl moieties have 1-8C, alkenyl or alkynyl moieties 2-8C, cycloalkyl moieties 3-12C and bi- or tri-cycloalkyl moieties 6-12C.
-
公开(公告)号:AT244725T
公开(公告)日:2003-07-15
申请号:AT97119639
申请日:1997-11-10
Applicant: HOECHST AG
Inventor: STILZ HANS ULRICH DR , WEHNER VOLKMAR DR , HUELS CHRISTOPH DR , SEIFFGE DIRK DR
IPC: C07D233/76 , A61K31/415 , A61K31/4166 , A61K38/00 , A61K38/05 , A61K38/06 , A61K38/07 , A61P3/08 , A61P9/00 , A61P9/10 , A61P11/00 , A61P19/02 , A61P29/00 , A61P33/02 , A61P35/00 , A61P37/00 , A61P37/08 , A61P43/00 , C07D233/54 , C07D233/72 , C07K5/02 , C07K5/023 , C07K5/06 , C07K5/08 , C07K5/10 , C07K5/117
Abstract: Use of N-substituted pyrrolidone, imidazolidinone, oxazolidinone or thiazolidinone derivatives of formula (I), in all stereoisomer or mixture forms, or their salts is for inhibiting the adhesion and/or migration of leukocytes or inhibiting VLA-4 receptors is new. W = R1-A-CR13 or R1A-CH=C; Y = CO, CS or CH2; Z = O, S or CH2 etc.; A = 1-6C alkylene, 3-12C cycloalkylene, (1-6C), phenylene-(1-6C)alkyl, or the divalent residue of a 5- or 6-membered ring containing 1 or 2 N (optionally mono- or disubstituted) etc.; B = 1-6C alkylene (optionally substituted), 2-6C alkenylene, phenylene, phenylene-(1-3C) alkyl or (1-3C) alkylene-phenyl; D = CR2R3. NR3 or CH=CR3; E = tetrazolyl, SO3H etc.; R = H, alkyl, cycloalkyl, cycloalkylalkyl, Ar, Ar-alkyl, Het' or Het'-alkyl (where alkyl residues are optionally substituted); R1 = H, 1-10C alkyl (optionally fluorinated), cycloalkyl, cycloalkylalkyl, O or S etc.; R2 = H, alkyl, Ar, Ar-alkyl or 3-8C cycloalkyl; R3 = H, alkyl, Ar, Ar-alkyl, 3-8C cycloalkyl, alkenyl, alkynyl, alkenylcarbonyl, alkynylcarbonyl, pyridyl etc.; R13 = H, 1-6C alkyl, Ar-alkyl or 3-8C cycloalkyl; b, c, d, f = 0 or 1, but not all 0; e, g, h= 0-6; Ar = optionally substituted 6-14C aryl; Het' = optionally substituted heteroaryl; unless specified otherwise alkyl moieties have 1-8C, alkenyl or alkynyl moieties 2-8C, cycloalkyl moieties 3-12C and bi- or tri-cycloalkyl moieties 6-12C.
-
公开(公告)号:CZ291733B6
公开(公告)日:2003-05-14
申请号:CZ360197
申请日:1997-11-13
Applicant: HOECHST AG
Inventor: STILZ HANS ULRICH DR , WEHNER VOLKMAR DR , HULS CHRISTOPH DR , SEIFFGE DIRK DR
IPC: C07D277/20 , A61K38/00 , A61K38/05 , A61K38/06 , A61K38/07 , A61P3/08 , A61P9/00 , A61P9/10 , A61P11/00 , A61P11/06 , A61P19/02 , A61P29/00 , A61P33/02 , A61P35/00 , A61P37/00 , A61P37/08 , A61P43/00 , C07D233/54 , C07D233/72 , C07D277/34 , C07K5/06 , C07K5/078 , C07K5/097 , C07K5/107 , C07K5/11 , C07K5/117
Abstract: In the present invention there are described compounds of the general formula I, which are inhibitors of leucocyte adhesion and migration and/or antagonists of VLA-4 adhesion receptor, which pertains to the group of integrins, as well as process of their preparation. The compounds of the general formula I can be used for treating or prophylaxis of diseases that are caused by undesired range of leucocyte adhesion and/or leucocyte migration or that are connected with undesired range of leucocyte adhesion and/or leucocyte migration or during which the cell-cell interactions or cell-matrix interactions play a role, which are based on interaction of VLA-4 receptors with ligands thereof, such as inflammatory processes, rheumatic arthritis or allergic diseases. There is further described a process for preparing the compounds of the general formula I, use of these compounds for preparing medicaments used for treating the above indicated diseases as well as pharmaceutical preparations that contain the compounds of the general formula I.
-
公开(公告)号:BR9705727A
公开(公告)日:2000-03-21
申请号:BR9705727
申请日:1997-12-14
Applicant: HOECHST AG
Inventor: STILZ HANS ULRICH DR , WEHNER VOLKMAR DR , KNOLLE JOCHEN DR , BARTNIK ECKART DR , HUELS CHRISTOPH
IPC: C07D233/00 , A61K31/415 , A61K31/4166 , A61K31/4178 , A61K31/421 , A61K31/426 , A61K38/00 , A61K38/06 , A61K38/07 , A61K38/39 , A61P3/08 , A61P9/00 , A61P9/10 , A61P11/00 , A61P19/02 , A61P29/00 , A61P33/02 , A61P35/00 , A61P37/00 , A61P37/08 , A61P43/00 , C07D233/32 , C07D233/72 , C07D233/74 , C07D233/76 , C07D233/86 , C07D257/00 , C07D403/12 , C07D405/12 , C07K5/02 , C07K5/023 , C07K5/078 , C07K5/08 , C07K5/097 , C07K5/10 , C07K5/117 , C07K7/06 , C07K14/78
Abstract: Use of N-substituted pyrrolidone, imidazolidinone, oxazolidinone or thiazolidinone derivatives of formula (I), in all stereoisomer (or mixture) forms, or their salts for inhibiting the adhesion and/or migration of leukocytes or inhibiting VLA-4 receptors is new. W = R1-A-CR13 or R1A-CH=C; Y = CO, CS or CH2; Z = O, S or CH2 etc.; A = 1-6C alkylene, 3-7C cycloalkylene, (1-6C) alkylene-phenylene, or the divalent residue of a 5- or 6-membered ring containing 1 or 2 N (optionally substituted); B = 1-6C alkylene (optionally substituted), 2-6C alkenylene, phenylene, phenylene-(1-3C) alkyl or (1-3C) alkylene-phenylene; D = CR2R3, NR3 or CH=CR3; E = tetrazolyl, SO3H etc.; R = H, alkyl, 3-8C cycloalkyl, Ar or Ar-alkyl ; R1 = X-NH-C(=NH)-(CH2)p or X1-NH-(CH2)p; p = 0-3; X = H, 1-6C alkyl, (1-6C) alkylcarbonyl, Ar-(1-6C) alkoxycarbonyl, CN, OH, etc.; X1 = X etc.; R2 = H, alkyl, Ar, Ar-alkyl or 3-8C cycloalkyl; R3 = H, alkyl, Ar, alkenyl, alkynyl, pyridyl etc.; R13 = H, 1-6C alkyl, Ar-alkyl or 3-8C cycloalkyl; b, c, d, f = 0 or 1, but not all 0; e, g, h= 0-6; Ar = optionally substituted 6-14C aryl; unless specified otherwise alkyl moieties have 1-8C, alkenyl or alkynyl moieties 2-8C, cycloalkyl moieties 3-12C and bi- or tri-cycloalkyl moieties 6-12C.
-
公开(公告)号:BR9705725A
公开(公告)日:1999-11-23
申请号:BR9705725
申请日:1997-11-14
Applicant: HOECHST AG
Inventor: STILZ HANS ULRICH DR , WEHNER VOLKMAR DR , HUELS CHRISTOPH DR , SEIFFGE DIRK DR
IPC: C07D277/20 , A61K38/00 , A61K38/05 , A61K38/06 , A61K38/07 , A61P3/08 , A61P9/00 , A61P9/10 , A61P11/00 , A61P11/06 , A61P19/02 , A61P29/00 , A61P33/02 , A61P35/00 , A61P37/00 , A61P37/08 , A61P43/00 , C07D233/54 , C07D233/72 , C07D277/34 , C07K5/06 , C07K5/078 , C07K5/097 , C07K5/107 , C07K5/11 , C07K5/117 , C07D233/80 , A61K31/415
Abstract: Use of N-substituted pyrrolidone, imidazolidinone, oxazolidinone or thiazolidinone derivatives of formula (I), in all stereoisomer or mixture forms, or their salts as medicaments is new. W = R1-A-CR13 or R1A-CH=C; Y = CO, CS or CH2; Z = O, S or CH2 etc.; A = direct bond, 3-12C cycloalkylene, (1-6C) alkylene-(3-12C) cycloalkylene, phenylene, or the divalent residue of a 5- or 6-membered ring containing 1 or 2 N (optionally mono- or disubstituted) etc.; B = 1-6C alkylene (optionally substituted), 2-6C alkenylene, phenylene, phenylene-(1-3C) alkyl or (1-3C) alkylene-phenylene; D = CR2R3, NR3 or CH=CR3; E = tetrazolyl, SO3H etc.; R = H, alkyl, cycloalkyl, cycloalkylalkyl, Ar, Ar-alkyl, Het' or Het '-alkyl (where alkyl residues are optionally substituted by one or more F); R1 = SR21, SSR21, SOR22, SO2R22, S-OR21, SO-OR21, SO2-OR21, SCOR21, SCOOR22, SCSSR22, OCOR21, OCSR21, OCOOR22, OSO2R22, OSO-R22, OP(O)(OR21)2, P(O)(OR21)2, P(O)(R22)OR21, CN, halo etc.; R2 = H, alkyl, Ar, Ar-alkyl or 3-8C cycloalkyl; R3 = H, alkyl, Ar, Ar-alkyl, 3-8C cycloalkyl, alkenyl, alkynyl, alkenylcarbonyl, alkynylcarbonyl, pyridyl etc.; R13 = H, 1-6C alkyl, Ar, Ar-alkyl, 3-8C cycloalkyl or (3-8C) cycloalkylalkyl; R21 = H, alkyl, hydroxyalkyl, alkenyl, cycloalkyl, cycloalkylalkyl, Ar, Ar-alkyl, Het' or Het'-alkyl (where alkyl residues are optionally substituted by one or more F); b, c, d, f = 0 or 1 provided not all are 0; e, g,h = 0-6; Ar = optionally substituted 6-14C aryl; Het' = optionally substituted heteroaryl; unless specified otherwise alkyl moieties have 1-8C, alkenyl or alkynyl moieties 2-8C, cycloalkyl moieties 3-12C and bi- or tri-cycloalkyl moieties 6-12C.
-
公开(公告)号:ID19253A
公开(公告)日:1998-06-28
申请号:ID973918
申请日:1997-12-18
Applicant: HOECHST AG , GENENTECH INC
Inventor: WEHNER VOLKMAR DR , STILZ HANS ULRICH DR , PEYMAN ANUSCHIRWAN DR , KNOLLE JOCHEN DR , RUXER JEAN MARIE DR , CARNIATO DENIS DR , LEFRANCOIS JEAN MICHEL , GADEK THOMAS RICHARD DR , MCDOWELL ROBERT DR
IPC: A61K31/155 , A61K31/16 , A61K31/18 , A61K31/33 , A61K31/395 , A61K31/415 , A61K31/4184 , C07D239/00 , A61K31/47 , A61K31/472 , A61K31/55 , A61K38/04 , A61P9/00 , A61P19/08 , A61P19/10 , A61P25/00 , A61P27/02 , A61P29/00 , A61P35/00 , A61P43/00 , C07C279/20 , C07C279/24 , C07C311/64 , C07C313/30 , C07C327/00 , C07D217/24 , C07D233/04 , C07D235/16 , C07D243/06 , C07D253/06 , C07D253/08 , C07D263/52 , C07D267/08 , C07D277/60 , C07D471/02 , C07D471/04 , C07D487/04 , C07K5/04 , C07K5/08 , A61K38/00 , A61K39/00 , A61K31/00 , C07D401/02 , C07D519/00
Abstract: Guanidine and cycloguanidine derivatives of formula A-B-D-E-F-G (I) and their salts are new. A = R R N-C(=NR )NR Z- or a group of formula (a) or (b); Z = C(Q) or S(O)n; Q = O or S; n = 1 or 2; R = 5-10 membered mono- or polycyclic, aromatic or non-aromatic ring (optionally containing 1-4 N, O and/or S and optionally substituted by 1 or more of R -R ); B = direct bond; or alkyl, -CR =CR -, 5-10C aryl, 3-8C cycloalkyl or -C IDENTICAL C- (all optionally mono- or disubstituted by 1-8C alkyl), e.g. Me-Ph-Me or Et-CH=CH-; D, F = direct bond or alkyl, 5-10C aryl, -Q-; -NR -, -CO-NR -, -NR -CO-, -NR -C(Q)-NR -, -O-C(O)-,-C(O)-O-, -C(Q)-, -S(O)n, -S(O)n-NR , -NR -S(O)n, -CR =CR -, -C IDENTICAL C-, -NR -N=CR -, -N=CR -, -R C=N- or -CH(OH)- (all optionally mono- or disubstituted by alkyl, -CR -CR - or 5-6C aryl), e.g. Me-Ph-CH=CH- or Et-O-, and D is optionally linked to B via one of these substituents; E = template of a fibrinogen receptor antagonist; G = -CR R -(CR R )p-(CH2)p-R ; R , R = H; 1-10C alkyl (optionally substituted by 1 or more F); cycloalkyl; cycloalkyl-alkyl; aryl; aryl-alkyl; R OC(O)R ; R R NC(O)R ; or R C(O)R ; R -R = H; F; OH; alkyl; cycloalkyl; cycloalkyl-alkyl; R QR ; R CO2R ; R OC(O)R ; R -5-14C aryl-R ; R N(R )R ; R R NR ; R N(R )CO(O)R ; R S(O)n-N(R )R ; R QC(O)N(R )R ; R C(O)N(R )R ; R N(R )C(O)N(R )R ; R N(R )S(O)N(R )R ; R S(O)nR ; R C(O)R ; R N(R )C(O)R ; or R N(R )S(O)nR ; R = H; Alk; cycloalkyl; cycloalkyl-Alk; aryl; or aryl-Alk; Alk = alkyl (optionally substituted by 1 or more F); R = direct bond or alkyl; R = C(Q)R ; S(O)n-NR ; P(O)nR ; or a 4-8 membered saturated or unsaturated heterocycle containing 1-4 N, O and/or S, e.g. tetrazolyl, imidazolyl, pyrazolyl, oxazolyl or thiadiazolyl; R = OH; alkoxy; aryl-alkoxy; aryloxy; alkylcarbonyloxy-(1-4C) alkoxy; aryl-alkylcarbonyloxy-(1-6C) alkoxy; NH2; NH(alkyl); N(alkyl)2; aryl-alkylamino; dialkylaminocarbonylmethoxy; aryl- dialkylaminocarbonylmethoxy; arylamino; or a L- or D-aminoacid; R -R = H; 1-10C alkyl (optionally substituted by one or more F); 3-12C cycloalkyl; 3-12C cycloalkyl-alkyl; aryl; aryl-alkyl; NH2; R ONR ; R OR ; R OC(O)R ; R R NR ; R -aryl-R ; HO-alkyl-N(R )R ; R N(R )C(O)R ; R C(O)N(R )R ; R C(O)R ; R R N-C(=NR )-NR ; R R N-C(=NR ); or Q; or two adjacent R R substituents form -O-(CH2)n-O- or -OC(CH3)2O-; p, q = 0 or 1; alkyl moieties have 1-8C, cycloalkyl moieties 3-14C and aryl moieties 5-14C unless specified otherwise; compounds where E is a 6-membered aromatic ring (optionally containing 1-4 N and/or 1-4 substituents ) and the compound 4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine are excluded.
-
公开(公告)号:ID19010A
公开(公告)日:1998-06-04
申请号:ID973670
申请日:1997-11-13
Applicant: HOECHST AG
Inventor: STILZ HANS ULRICH DR , WEHNER VOLKMAR DR , KNOLLE JOCHEN DR , BARTNIK ECKART DR , HULS CHRISTOPH DR
IPC: A61K31/415 , A61K31/4166 , A61K31/4178 , C07D233/00 , A61K31/421 , A61K31/426 , A61K38/00 , A61K38/06 , A61K38/07 , A61K38/39 , A61P3/08 , A61P9/00 , A61P9/10 , A61P11/00 , A61P19/02 , A61P29/00 , A61P33/02 , A61P35/00 , A61P37/00 , A61P37/08 , A61P43/00 , C07D233/32 , C07D233/72 , C07D233/74 , C07D233/76 , C07D233/86 , C07D257/00 , C07D403/12 , C07D405/12 , C07K5/02 , C07K5/023 , C07K5/078 , C07K5/08 , C07K5/097 , C07K5/10 , C07K5/117 , C07K7/06 , C07K14/78 , C07D263/08 , C07D277/08 , A61K31/41
Abstract: Use of N-substituted pyrrolidone, imidazolidinone, oxazolidinone or thiazolidinone derivatives of formula (I), in all stereoisomer (or mixture) forms, or their salts for inhibiting the adhesion and/or migration of leukocytes or inhibiting VLA-4 receptors is new. W = R1-A-CR13 or R1A-CH=C; Y = CO, CS or CH2; Z = O, S or CH2 etc.; A = 1-6C alkylene, 3-7C cycloalkylene, (1-6C) alkylene-phenylene, or the divalent residue of a 5- or 6-membered ring containing 1 or 2 N (optionally substituted); B = 1-6C alkylene (optionally substituted), 2-6C alkenylene, phenylene, phenylene-(1-3C) alkyl or (1-3C) alkylene-phenylene; D = CR2R3, NR3 or CH=CR3; E = tetrazolyl, SO3H etc.; R = H, alkyl, 3-8C cycloalkyl, Ar or Ar-alkyl ; R1 = X-NH-C(=NH)-(CH2)p or X1-NH-(CH2)p; p = 0-3; X = H, 1-6C alkyl, (1-6C) alkylcarbonyl, Ar-(1-6C) alkoxycarbonyl, CN, OH, etc.; X1 = X etc.; R2 = H, alkyl, Ar, Ar-alkyl or 3-8C cycloalkyl; R3 = H, alkyl, Ar, alkenyl, alkynyl, pyridyl etc.; R13 = H, 1-6C alkyl, Ar-alkyl or 3-8C cycloalkyl; b, c, d, f = 0 or 1, but not all 0; e, g, h= 0-6; Ar = optionally substituted 6-14C aryl; unless specified otherwise alkyl moieties have 1-8C, alkenyl or alkynyl moieties 2-8C, cycloalkyl moieties 3-12C and bi- or tri-cycloalkyl moieties 6-12C.
-
-
-
-
-
-
-
-
-